An Investigation Has Commenced on Behalf of Supernus Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SUPN Losses
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for potential federal securities law violations. This follows the company's announcement that its Phase 2b study of SPN-820 for treatment-resistant depression did not meet its primary endpoint.
March 03, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Supernus Pharmaceuticals faces an investigation by Levi & Korsinsky for potential securities law violations after its SPN-820 study failed to meet primary endpoints.
The failure of the SPN-820 study is a significant setback for Supernus Pharmaceuticals, potentially affecting investor confidence and leading to legal challenges. The investigation by Levi & Korsinsky could result in further negative sentiment and pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100